Cantabio Pharmaceuticals, Inc. (CTBO)
Cantabio Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Palo Alto, CA, US. The stock last traded at $1.01, up 0.00% on the session, giving a market capitalisation of $22,769. Its beta of 456.60 implies it has historically moved more than the broad market.
Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company, which engages in the commercialization of novel therapies and the intellectual property generated from the research and development activities for Parkinson's, Alzheimer's diseases, and any other related diseases. It focuses on identification and development of small molecule pharmacological chaperones targeting proteins that misfold and aggregated in vivo vivo levels of proteins which display loss of function during disease conditions. The company was founded by Gergely Toth on February 6, 2012 and is headquartered in Palo Alto, CA.
Cantabio Pharmaceuticals, Inc. is most often compared with the following Healthcare names: